Materia, the mother company of Materia Malta, announced that it has commenced sales of the first medical cannabis flower produced at its EU GMP certified manufacturing site.

‘Carbasi Verde’, the company’s inaugural product, can now be purchased from pharmacies all over the islands and will be shipped out to Germany and the UK.

“The journey began in earnest over two years ago, so we’re elated to be offering patients Materia manufactured and branded medical cannabis,” Materia’s Europe Managing Director, Nick Pateras, said.

“Out Maltese site is truly state-of-the-art, and with our team’s deep pharmaceuticals expertise we’re confident that Materia Malta will become one of the most important production facilities in Europe’s cannabis supply chain,” he continued.

‘Carbasi Verde’ was released into the market with a potency of 21.7% THC, following successful completion of Materia Malta’s first production cycle.

“Materia has been at the forefront of Malta’s cannabis industry since we moved quickly to become a European leader in this field,” Malta Enterprise CEO Kurt Farrugia said, congratulating the company.

“We’re extremely proud to see locally produced medicinal products available to Maltese patients and are excited to continue supporting Materia’s talented team as the company expands its presence across the content,” he concluded.

Related

KDM Group names John Bartolo Group Chief Commercial Officer

13 March 2026
by Nicole Zammit

He says he is 'excited for the journey ahead.'

APS CEO says bank could tap into digital currencies to take advantage of disruption   

13 March 2026
by Tim Diacono

Marcel Cassar says APS views disruption to traditional banking as a potential opportunity.

Steves&Co. – 20 years and counting

13 March 2026
by MaltaCEOs

Twenty years of building brands, shaping experiences, staying curious.

APS CEO eyes further growth after ‘standout’ 2025 performance

12 March 2026
by Nicole Zammit

Marcel Cassar says the bank's strategy 'clearly paid off' as it registered 'broad-based double-digit growth over 2024.'